Source notes

Caffeine and a carefully targeted medicine can act on the same signaling system without doing the same job. Both can block adenosine receptors, proteins that respond to a chemical messenger. Caffeine affects several receptor types, while the medicines discussed aim more selectively at A2A. The paper traces how this difference shapes drug development, especially for Parkinson’s disease. It also reports that caffeine’s half-life in healthy adults is commonly about 4–5 hours: roughly the time for its amount in the body to fall by half. That duration varies between people and is not a universal clearance time.

The strongest caution concerns disease prevention. Associations between coffee or caffeine consumption and lower Parkinson’s risk do not establish that caffeine prevents the disease. Coffee also contains other active substances. Separately, a targeted drug’s effect on symptoms is not proof that it slows the underlying disease. These are different questions, even when the same receptor appears in the explanation.

How Does This Show Up in Real Life?

An afternoon coffee and a medicine designed around A2A should not be treated as interchangeable ways to protect the brain. The useful question is what the human evidence actually measured: alertness, symptoms, or future disease. For everyday understanding, the half-life estimate also means that “the effect feels weaker” and “the caffeine is gone” are different statements. It does not identify a bedtime cutoff that suits everyone. The paper provides pharmacological context, not an individualized caffeine schedule. A claim that an ingredient blocks a receptor may explain why researchers study it, but it still leaves unanswered whether the product, amount, and intended use have been tested. This is a reason to separate a mechanism from the promise attached to it.

The evidence ranges from molecular experiments to observational research and drug trials, so it cannot support one common estimate of benefit. Some promising selective compounds failed to show useful clinical effects, and others encountered safety problems. The article does not establish durable brain protection from habitual caffeine use. Its account of drug development also reflects evidence available at publication.

Treat this as a guide to the questions behind a health claim, not a reason to start a prevention strategy. A convincing molecular story becomes useful treatment evidence only when the particular intervention and the outcome that matters have been tested together.